Cardiovascular problems after allogeneic stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows patients undergoing allogeneic HSCT to document cardiovascular events such as heart dysfunction, arrhythmias, and acute coronary syndrome. It aims to identify potential predictive factors, including biomarkers like DPP3, and to understand how conditioning and maintenance regimens influence cardiotoxic risk. The research builds on ESC guidelines recommending routine cardiac monitoring and biomarker testing in HSCT patients. The investigation leverages data from multiple French centers to improve understanding of mechanisms and follow-up needs. Interventions are not specified, and overall insights are intended to guide future preventive and management strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 15 years
* Informed about the study and without objection to participation (or with consent from legal guardians)
* Undergoing allogeneic HSCT

Exclusion Criteria:

* Patient not followed up at the participating center
* Pregnant or breastfeeding women
* Patient not affiliated with social security
* Patient under guardianship, curatorship, or legal protection

Where it's running

• Saint Louis Hospital
  Paris, France Recruiting

Study contacts

• Study coordinator: Trecy Dr Gonçalves, Dr
• Email: trecy.goncalves@aphp.fr
• Phone: +33142499162

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD

  This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.

  Recruiting at 2 sites Early Phase 1 Valley Health System · Paramus, New Jersey and 1 other locations · NCT07837830

• See how well the lungs distribute dissolved xenon gas during MRI in HSCT patients and others

  This study tests a special MRI method using hyperpolarized xenon gas to visualize how gas and dissolved xenon move through the lungs in people who have HSCT, respiratory issues, or are healthy controls.

  Recruiting Phase 1/2 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07823036

• Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension

  This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.

  Recruiting Hospital de Clinicas de Porto Alegre · Porto Alegre · NCT07822997

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.